Big Data strategies face big obstacles as well as big rewards. Research analysts recently discussed problems plaguing Big Data- and analytics-driven teams with pharmaceutical and medical device executives. Similar concerns arose: How do we keep data secure and maintain patient privacy? How can we all benefit by sharing data? How do we sift through complex and unreliable information? Below, executives express their concerns and predictions for meeting these challenges and realizing the full impact of Big Data. Continue reading “Challenges of Big Data Loom Large Over Pharma” »
By Christie Shilling,
The latest buzzword among pharma sales management is “customer-centric.” Especially with the Sunshine Act legislation having finally been implemented, companies are looking for any way to remodel their sales teams so as not to end up on the list of payments to doctors. Many hope that a customer-centric strategy is the answer to a lot of their regulatory and compliance woes. Preliminary findings from our latest sales survey show that 68% of companies either have implemented or are planning to implement a customer-centric approach to sales. Continue reading “‘Customer-Centric’ Sales Strategies: How Will This Benefit Pharma?” »
In recent years, adaptive clinical trials have become popular among drug developers due to their flexibility and efficiency. Adaptive trial designs allow clinical teams to modify current trials by unblinding data during an interim phase of the trial. Often, this flexibility allows teams to make adjustments to dosages, eliminate treatment arms or even terminate trials early. Many R&D teams were hesitant to embrace these designs. However, contract research organization Medelis suggests that nearly 20% of the pharmaceutical industry has adopted adaptive trials. This number is on the rise, and many companies may be swayed by the success of Gilead’s recent adaptive clinical trial success. Continue reading “Positive Risk-Benefit Findings Prompt Gilead to Stop Leukemia Phase 3 Trials Early” »
They say that space is the final frontier – or at least they say so in Star Trek – and this may very well be true. For pharma marketing, however, the next frontier is something a little closer to home: websites, smartphones, tablets and social media. Through these media channels, digital marketing has the ability to reach a larger and more targeted audience by putting awareness, education and advocacy literally at consumers’ fingertips. Continue reading “The Next Frontier: Measuring ROI of Digital Marketing” »
With another patent cliff looming, many pharmaceutical and biotechnology companies are expanding their clinical pipelines — be it to incorporate new therapies, to concentrate on niche areas or to develop new mechanisms of action (MoAs). Often, companies develop these strategies to address existing unmet medical needs. From companies’ clinical structures to their marketing strategies, it’s common knowledge that one size rarely fits all. In the same vein, rarely does a single MoA effectively treat all patients within a disease state.
Continue reading “When Reinventing the Wheel Is a Good Thing: Developing New Mechanisms of Action to Target Unmet Medical Needs” »
As more of the population relies on smartphones and tablet technology, the pharmaceutical industry is looking to mobile marketing to reach its customers. Within the healthcare industry, both doctors and patients use mobile technology for different purposes. Doctors look to mobile medical device solutions such as Mobile MIM to view medical images on their mobile devices, as well as other applications to connect with their peers and to find treatment information and solutions. Patients use mobile applications to track their health and fitness levels and to manage chronic disease states. Continue reading “Three Steps Pharma Can Take to Make the Most of the Mobile Marketplace” »
The pharmaceutical industry has always turned to experts and key opinion leaders to shape and inform company policy. Despite increasing rules on how companies are allowed to interact with physicians, this role will continue to be important in order to further the effective development of medicines and ensure that the benefits of therapies are being communicated to physicians in a useful format. Continue reading “Discussion Leader and Clear Goals Set Pharmaceutical Advisory Boards Up for Success” »
“A flat prediction I’ll make,” claimed esteemed advertising guru Jerry Della Femina in a New York Times article written in October 1982, just days after arsenic-laced Tylenol fatally poisoned seven Chicagoans, “is that you will not see the name ‘Tylenol’ in any form within a year. I don’t think they can ever sell another product under that name. There may be an advertising person who thinks he can solve this, and if they find him I want to hire him, because then I want him to turn our water cooler into a wine cooler.” Continue reading “The Headaches Behind Warning Labels: Tylenol Put Patients First, Brand Second” »
If it looks like a medical device and it works like a medical device, it’s probably a medical device.
App developers, the wait is over! The FDA has finally released its guidance on mobile medical applications. The guidance describes the types of apps that are covered under FDA oversight and those left to the discretion of app developers. Continue reading “New Mobile Health Application Guidelines: The Regulatory Impact on Developers” »